Clinical trials: Ejection Fraction
Cardiovascular Diseases
Effect of Rehabilitation on Ejection Fraction (FE) in Cardiopathic and Non Cardiopathic Patients Undergoing Major Orthopedic Surgery
It is a trial aimed to evaluate the ejection fraction in the preoperative phase and during follow-up in two groups of subjects undergoing major orthopedic surgery: the first consisting of subjects without history of cardiac…
- Trial name
- NCT03413345
- Where
- Italy
- Volunteers
- 1 people
- Sponsor
- I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio
CABG in Low EF
Early Outcome in Unstable Angina Patients With Low EF After CABG
Coronary artery bypass grafting (CABG) among patients with reduced myocardial function remains a surgical challenge despite improvement in surgical technique, myocardial protection and postoperative care.
- Trial name
- NCT03276624
- Testing
- CABG
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- Assiut University
Heart Failure, Heart Failure, Systolic
Hemodynamic-GUIDEd Management of Heart Failure
The GUIDE-HF IDE clinical trial is intended to demonstrate the effectiveness of the CardioMEMS™ HF System in an expanded patient population including heart failure (HF) patients outside of the present indication, but at risk for…
- Conditions
- Heart Failure, Heart Failure, Systolic, Heart Failure, Diastolic, Heart Failure NYHA Class II
- Trial name
- GUIDE-HF (NCT03387813)
- Testing
- CardioMEMS™ HF System
- Where
- 129 sites in United States, Canada
- Volunteers
- 2,358 people
- Sponsor
- Abbott Medical Devices
Anemia
Anemia in Heart Failure With a Preserved Ejection Fraction (HFPEF)
The purpose of this study is to determine if treating anemia with subcutaneous erythropoetin in patients with heart failure and a preserved ejection fraction (HFPEF) will be associated with reverse ventricular remodeling…
- Trial name
- NCT00286182
- Testing
- Erythropoietin alpha
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Mathew S. Maurer
Pulmonary Hypertension, Heart Failure With Reduced Ejection Fraction
A Randomized Placebo-procedure Controlled Trial of the Enhancor System (PULmonary Artery Denervation) to Evaluate Safety and Efficacy in Patients With Combined Pre- and Post-capillary Pulmonary Hypertension Associated With Left Heart Disease
The goal of this clinical study is to evaluate the safety and efficacy of percutaneous pulmonary artery denervation with the Multi-Pole Pulmonary Artery Radiofrequency Ablation Enhancor System in patients with combined pre- and…
- Conditions
- Pulmonary Hypertension, Heart Failure With Reduced Ejection Fraction, Hypertension, Vascular Diseases
- Trial name
- The PULSE-LHD (NCT07214376)
- Testing
- Pulmonary Artery Denervation (PADN)
- Where
- 18 sites in United States, China
- Volunteers
- 750 people
- Sponsor
- Pulnovo Medical, Inc.
Heart Failure With Preserved Ejection Fraction
Study of Sacubitril/ValsarTan on MyocardIal OxygenatioN and Fibrosis in Heart Failure With Preserved Ejection Fraction
To assess the effect of ARNI on myocardial deoxygenation at stress and myocardial fibrosis, and correlate this to changes in myocardial systolic and diastolic function in HFpEF patients.
- Trial name
- PRISTINE-HF (NCT04128891)
- Testing
- Sacubitril-Valsartan
- Sponsor
- Flinders University
HFrEF - Heart Failure With Reduced Ejection Fraction, Guideline Adherence
Guideline Implementation and Quality of Care Evaluation in Patients With Heart Failure and Reduced Ejection Fraction (HFrEF)
The IMPLEMENT HF study is part of the national heart failure quality of care registry (evaluation of given health care). Within the HF registry, the investigators will investigate whether mirror information on the actual 4…
- Trial name
- IMPLEMENT HF (NCT07702760)
- Where
- Netherlands
- Volunteers
- 1,500 people
- Sponsor
- Jasper Brugts MD PhD
Heart Failure With Reduced Ejection Fraction
Phase Ib/IIa Trial With AC01 in Patients With HFrEF
This is a randomized, double-blind, placebo-controlled two-part study with a multiple escalating dose phase followed by a cohort expansion phase to assess safety, tolerability, pharmacokinetics and pharmacodynamics of AC01 in…
- Trial name
- GOAL-HF1 (NCT05642507)
- Testing
- AC01
- Where
- 14 sites in Italy, Netherlands and 2 more
- Volunteers
- 58 people
- Sponsor
- AnaCardio AB
Coronary Artery Bypass, Cardiopulmonary Bypass
Role of Glutamine as Myocardial Protector in Elective On-Pump CABG Surgery With Low EF
Coronary artery disease has the highest mortality rate worldwide and coronary artery bypass grafting (CABG) is the most common cardiac surgery performed in patients with coronary artery disease to revascularize the heart.
- Conditions
- Coronary Artery Bypass, Cardiopulmonary Bypass, Coronary Artery Disease
- Trial name
- NCT04560309
- Testing
- L-alanyl-L-glutamine dipeptide
- Where
- Indonesia
- Volunteers
- 60 people
- Sponsor
- National Cardiovascular Center Harapan Kita Hospital Indonesia
Heart Failure With Reduced Ejection Fraction
Dashboard Activated Services and Tele-Health for Heart Failure
The Dashboard Activated Services and tele-Health for Heart Failure (DASH-HF) study is a pragmatic randomized controlled trial of a quality improvement (QI) intervention of a prospective panel management intervention to optimize…
- Trial name
- DASH-HF (NCT05001165)
- Testing
- Proactive Panel Management Clinics for HFrEF
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- VA Greater Los Angeles Healthcare System
Heart Failure With Preserved Ejection Fraction
A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients
The purpose of this study is to demonstrate the superiority of LCZ696 over individualized medical therapy for comorbidities in reducing N-terminal pro-brain natriuretic peptide (NT-proBNP) and improving exercise capacity and HF…
- Trial name
- PARALLAX (NCT03066804)
- Testing
- sacubitril/valsartan, Enalapril, Valsartan
- Where
- 380 sites in United States, Argentina and 30 more
- Volunteers
- 2,572 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction
Safety and Efficacy Trial to Treat Diastolic Heart Failure Using Ambrisentan
This is a randomized study of ambrisentan that will last 16 weeks. The study will include patients with diastolic heart failure and pulmonary hypertension. Patients will be randomized (1:1) to ambrisentan or placebo.
- Trial name
- NCT00840463
- Testing
- Ambrisentan
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Texas Southwestern Medical Center
Heart Failure，Congestive
Effects of Furosemide Plus Small HSS in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF)
The investigators sought to evaluate the effectiveness of treatment with furosemide + HSS in terms of reduction of serum levels of some chosen markers of heart failure and the response in terms of these markers at a compensated…
- Trial name
- NCT04628325
- Testing
- Furosemide
- Where
- 2 sites in Italy
- Volunteers
- 136 people
- Sponsor
- University of Palermo
Heart Failure With Preserved Ejection Fraction, Microvascular Dysfunction
Empagliflozin for Peripheral Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction
The goal of this low-intervention clinical trial is to learn about the effect of the drug Empagliflozin in patients with heart failure with preserved ejection fraction.
- Trial name
- NCT06046612
- Testing
- Participants receive 10mg Empaglifozin once daily on prescription from their treating physician. This is not an intervention in this trial, but part of their normal HFpEF treatment
- Where
- Netherlands
- Volunteers
- 48 people
- Sponsor
- Maastricht University Medical Center
Heart Failure, Heart Failure With Reduced Ejection Fraction
Gender-based Differences in the Outcome of Treatment With Aldosterone Antagonists in Patients With Heart Failure
Heart failure (HF) is a major healthcare problem. In patients with Heart Failure with Reduced Ejection Fraction (HFrEF), aldosterone antagonists reduce mortality and hospitalization rate.
- Conditions
- Heart Failure, Heart Failure With Reduced Ejection Fraction, Heart Failure NYHA Class II, Heart Failure NYHA Class III
- Trial name
- GBDAL-HF (NCT06233695)
- Testing
- Potassium sparing diuretic
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Alexandria University
Heart Failure With Reduced Ejection Fraction, Chronic Heart Failure
Vericiguat and Exercise Hemodynamics in Patients With HFrEF
Heart failure with reduced ejection fraction (HFrEF) is associated with impaired exercise capacity and abnormal exercise hemodynamics despite contemporary guideline-directed medical therapy (GDMT).
- Trial name
- EVERHETT-HF (NCT07697365)
- Testing
- Vericiguat, Guideline-directed medical therapy (GDMT) for heart failure
- Where
- Greece
- Volunteers
- 40 people
- Sponsor
- Argyrios Ntalianis
Heart Failure With Preserved Ejection Fraction
A Study of Mavacamten in Participants With HFpEF and Elevation of NT-proBNP With or Without Elevation of cTnT
This is a Phase 2a proof-of-concept study to assess safety, tolerability, and preliminary efficacy of mavacamten treatment on biomarker levels in participants with heart failure with preserved ejection fraction (HFpEF) and…
- Trial name
- EMBARK-HFpEF (NCT04766892)
- Testing
- mavacamten
- Where
- 21 sites in United States, Canada
- Volunteers
- 30 people
- Sponsor
- Bristol-Myers Squibb
Amyloidosis Cardiac, Heart Failure
Cardiac Contractility Modulation Therapy in Amyloid Cardiomyopathy Patients With Heart Failure
The primary aim of this observational registry is to evaluate the efficacy of CCM in patients with heart failure with mid-range or reduced EF and diagnosis of TTR amyloidosis.
- Trial name
- AMY-CCM (NCT05167799)
- Testing
- Cardiac Contractility Modulation (CCM)
- Where
- Italy
- Volunteers
- 25 people
- Sponsor
- Ospedale C & G Mazzoni
Heart Failure With Reduced Ejection Fraction
Improving CRT Outcome With Non-Invasive Cardiac Mapping
The ICONIC-M study is a multicenter randomized controlled study to assess patient response to CRT comparing ECGI map guided left ventricular lead placement with empirical lead placement.
- Trial name
- ICONIC-M (NCT05564793)
- Testing
- Pre-implantation planning, Post-implantation assessment
- Where
- 11 sites in Netherlands, Portugal and 2 more
- Volunteers
- 330 people
- Sponsor
- EP Solutions SA
Heart Failure With Reduced Ejection Fraction (HF-rEF)
Study of Efficacy and Safety of LCZ696 in Japanese Patients With Chronic Heart Failure and Reduced Ejection Fraction
The purpose of this study was to assess the effect of LCZ696 at a target dose of 200 mg b.i.d. compared to enalapril 10 mg b.i.d., in addition to the background heart failure (HF) treatment, on delaying time to first occurrence…
- Trial name
- PARALLEL-HF (NCT02468232)
- Testing
- LCZ696, Enalapril
- Where
- 49 sites in Japan
- Volunteers
- 225 people
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.